Table 1.

HLA-DR53 Restriction of the Proliferative Response of HO-1 to the DEK-CAN Fusion Peptide

Clone APC MoAb Added Peptide StimulationProliferative Response (cpm) (mean ± SD)
Experiment No. 1*
 
HO-1  Auto PBMCs None  +  23,084 ± 1,395  
   − 129 ± 24  
  Anti–HLA-DR  +  209 ± 15 
  Anti–HLA-DQ  +  29,599 ± 1,461 
  Anti–HLA-DP  +  18,138 ± 151 
Experiment No. 2
 
HO-1 None   +  604 ± 48  
   −  89 ± 8 
 L-Neo   +  271 ± 25  
   − 213 ± 20  
 L-DR4   +  640 ± 139 
   −  764 ± 150  
 L-DR53   24,475 ± 1,227  
   −  242 ± 46  
None L-DR53   +  367 ± 188  
   − 227 ± 25 
Clone APC MoAb Added Peptide StimulationProliferative Response (cpm) (mean ± SD)
Experiment No. 1*
 
HO-1  Auto PBMCs None  +  23,084 ± 1,395  
   − 129 ± 24  
  Anti–HLA-DR  +  209 ± 15 
  Anti–HLA-DQ  +  29,599 ± 1,461 
  Anti–HLA-DP  +  18,138 ± 151 
Experiment No. 2
 
HO-1 None   +  604 ± 48  
   −  89 ± 8 
 L-Neo   +  271 ± 25  
   − 213 ± 20  
 L-DR4   +  640 ± 139 
   −  764 ± 150  
 L-DR53   24,475 ± 1,227  
   −  242 ± 46  
None L-DR53   +  367 ± 188  
   − 227 ± 25 
*

Incorporation of 3H-TdR into HO-1 cells was determined in the presence of autologous APCs with or without DEK-CAN peptide and with or without anti-HLA MoAb.

Incorporation of 3H-TdR into HO-1 cells was determined in the presence or absence of various types of APC with or without DEK-CAN peptide.

Close Modal

or Create an Account

Close Modal
Close Modal